-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED Reports 2026 Interim Results

Barchart·07/30/2026 06:00:00
Listen to the news

— China product sales recovery continues led by ELUNATE® and SULANDA® with over 40% growth each —

— FRUZAQLA® ex-US sales driving growth – now approved or launched in 41 countries —

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.